- Raised $43M funding round, Nov 2021
- Raised $68.5M funding round led by Forbion Capital Partners, Jun 2020
- Raised $11M funding round, Apr 2022
About
Prilenia is a late clinical-stage biotechnology company founded in 2018 focused on the urgent mission to develop novel therapeutics to address the progression of neurodegenerative diseases and neurodevelopmental disorders. The initial focus of the company has been on Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS).
Prilenia's lead compound is pridopidine (45 mg twice daily), a first-in-class, oral, highly selective and potent investigational S1R agonist that is in pre-registration for HD and Phase 3-stage development for ALS. Prilenia holds Orphan Drug designation for pridopidine in HD and ALS in the U.S. and EU. In addition, pridopidine has received Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of HD.
Prilenia is backed by a group of well-respected investors including: Forbion, Morningside, Sands Capital, SV Health Investors, Sectoral Asset Management, Talisman, Amplitude Ventures and the ALS Investment Fund.
Funding history · 4 rounds · $144.5M total
Q&A
- What is Prilenia Therapeutics' primary focus?
- Prilenia Therapeutics is a late clinical-stage biotechnology company focused on developing novel therapeutics to address the progression of neurodegenerative diseases and neurodevelopmental disorders, specifically Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS).
- What is Prilenia Therapeutics' lead compound?
- Prilenia Therapeutics' lead compound is pridopidine (45 mg twice daily), an oral, highly selective, and potent investigational S1R agonist. It is in pre-registration for Huntington's disease (HD) and Phase 3-stage development for amyotrophic lateral sclerosis (ALS).
- Has pridopidine received any special designations?
- Yes, pridopidine holds Orphan Drug designation for Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS) in the U.S. and EU. Additionally, it has received Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of HD.
- When was Prilenia Therapeutics founded?
- Prilenia Therapeutics was founded in May 2018.
- What is the total amount of funding Prilenia Therapeutics has raised?
- Prilenia Therapeutics has raised a total of $144,500,000 USD.
- When was Prilenia Therapeutics' most recent funding round and how much was raised?
- Prilenia Therapeutics' most recent funding round occurred in April 2022, raising $11,000,000 USD.
- Which investors participated in Prilenia Therapeutics' June 2020 funding round?
- The June 2020 funding round included Forbion Capital Partners.
- How many employees does Prilenia Therapeutics have?
- Prilenia Therapeutics has 51–200 employees.
- Where are Prilenia Therapeutics' offices located?
- Prilenia Therapeutics has offices in Yakum, Israel; Naarden, Netherlands; and Waltham, MA, USA.
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | prilenia.com |
|---|---|
| linkedin.com/company/26568559 |
Identifiers & details
| Founded | 2018-5 |
|---|---|
| Employees (exact) | 56 |
| Offices | Naarden; Waltham |
Radar intelligence
Open jobs — lever
| Total open | 3 |
|---|---|
| Remote | 0 |
| By department | Quality (1), Medical Affairs (1), Clinical Operations (1) |
| By location | Boston, MA (3) |
| Title | Location | Department |
|---|---|---|
| Director / Senior Director, GCP Quality Assurance Lead (US/IL/EU) | Boston, MA | Quality |
| Medical Science Liaison – Neurodegeneration (United States) | Boston, MA | Medical Affairs |
| Regional Clinical Trial Manager - East Coast, US | Boston, MA | Clinical Operations |
Patents
| EPO | 12 |
|---|
Web history (Wayback)
| Domain | prilenia.com |
|---|
Certificate / subdomain footprint
| Subdomains | 4 |
|---|